Literature DB >> 22069180

Guidelines for good database selection and use in pharmacoepidemiology research.

Gillian C Hall1, Brian Sauer, Alison Bourke, Jeffrey S Brown, Matthew W Reynolds, Robert LoCasale, Robert Lo Casale.   

Abstract

The use of healthcare databases in research provides advantages such as increased speed, lower costs and limitation of some biases. However, database research has its own challenges as studies must be performed within the limitations of resources, which often are the product of complex healthcare systems. The primary purpose of this document is to assist in the selection and use of data resources in pharmacoepidemiology, highlighting potential limitations and recommending tested procedures. This guidance is presented as a detailed text with a checklist for quick reference and covers six areas: selection of a database, use of multiple data resources, extraction and analysis of the study population, privacy and security, quality and validation procedures and documentation.
Copyright © 2011 John Wiley & Sons, Ltd.

Mesh:

Year:  2011        PMID: 22069180     DOI: 10.1002/pds.2229

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  38 in total

Review 1.  Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies.

Authors:  Edward Chia-Cheng Lai; Nicole Pratt; Cheng-Yang Hsieh; Swu-Jane Lin; Anton Pottegård; Elizabeth E Roughead; Yea-Huei Kao Yang; Jesper Hallas
Journal:  Eur J Epidemiol       Date:  2017-07-11       Impact factor: 8.082

2.  Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight.

Authors:  Pierre Engel; Mariana Ferreira Almas; Marieke Louise De Bruin; Kathryn Starzyk; Stella Blackburn; Nancy Ann Dreyer
Journal:  Br J Clin Pharmacol       Date:  2016-12-07       Impact factor: 4.335

Review 3.  Preparing for safety issues following drug approval: pre-approval risk management considerations.

Authors:  Gretchen S Dieck; Robert G Sharrar
Journal:  Ther Adv Drug Saf       Date:  2013-10

4.  RETRACTED ARTICLE: The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 6 Years After Approval.

Authors:  Elisa Martín-Merino; Ana Llorente-García; Dolores Montero Corominas; Consuelo Huerta-Álvarez
Journal:  Pharmaceut Med       Date:  2019-04

5.  The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval.

Authors:  Elisa Martín-Merino; Ana Llorente-García; Belén Castillo Cano; Dolores Montero Corominas; Consuelo Huerta-Álvarez
Journal:  Pharmaceut Med       Date:  2019-12

6.  Data quality assessment for comparative effectiveness research in distributed data networks.

Authors:  Jeffrey S Brown; Michael Kahn; Sengwee Toh
Journal:  Med Care       Date:  2013-08       Impact factor: 2.983

7.  An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance.

Authors:  Xiaofeng Zhou; Sundaresan Murugesan; Harshvinder Bhullar; Qing Liu; Bing Cai; Chuck Wentworth; Andrew Bate
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

Review 8.  Challenges in evaluating cancer as a clinical outcome in postapproval studies of drug safety.

Authors:  Simone P Pinheiro; Donna R Rivera; David J Graham; Andrew N Freedman; Jacqueline M Major; Lynne Penberthy; Mark Levenson; Marie C Bradley; Hui-Lee Wong; Rita Ouellet-Hellstrom
Journal:  Ann Epidemiol       Date:  2016-08-31       Impact factor: 3.797

Review 9.  Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer.

Authors:  Lorena Rocha Ayres; André de Oliveira Baldoni; Anna Paula de Sá Borges; Leonardo Régis Leira Pereira
Journal:  Int J Clin Pharm       Date:  2013-08-11

10.  Who diagnosed and prescribed what? Using provider details to inform observational research.

Authors:  Greta A Bushnell; Til Stürmer; Christina Mack; Virginia Pate; Matthew Miller
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-10-31       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.